Our preclinical studies have demonstrated that SIAH-dependent proteolysis is a key tumor vulnerability and an “Achilles’ heel” for oncogenic K-RAS-driven high-grade and malignant tumors [72,134,135]. The gene discussed is KRAS; the disease is cancer.